Feng Huang, Zhong Ming Liu and Song Guo Zheng* Pages 345 - 349 ( 5 )
Background: Autoimmune disease is a refractory disease. Accumulating Evidence has revealed that the manipulation of mesenchymal stem cells may have the potential to control or even treat autoimmune diseases. Human gingiva-derived mesenchymal stem cells (GMSCs) are emerging as a new line of mesenchymal stem cells that have displayed some potential advantages in controlling and treating autoimmune diseases.
Objective: In this review, we briefly update the current understanding on the biology of GMSCs and their effects on preventing and treating autoimmune diseases.
Conclusion: The availability of gingival mesenchymal stem cells (GMSCs), together with their potent capacity of multi-directional differentiation and inflammatory modulation, making GMSCs an ideal subtype of MSCs in treating autoimmune disease. Our and other studies have launched the earliest appraisal on GMSCs and carried out a lot of biological researches. The clinical trial of GMSCs on patients with autoimmune diseases will further approve their therapeutic effects, as well as its cellular and molecular mechanisms.
Autoimmune diseases, mesenchymal stem cells, human gingiva-derived mesenchymal stem cells, bone marrowderived mesenchymal stem cells, cell therapy.
Department of Clinical Immunology, Third Hospital at Sun Yat-sen Universirty, Guangzhou, 510630, Institute of Immunology, Shanghai East Hospital at Tongji University, Shanghai, 200120, Department of Medicine, Milton S. Hershey Medical Center, Penn State University, Hershey, PA, 17033